Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, has been approved by FDA for treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation in the CFTR gene. This agent offers a novel approach to the treatment of cystic fibrosis, as it is the only marketed drug that targets the underlying cause of this lethal condition, instead of the downstream disease processes that occur as a result of lacking or defective CFTR.
Current use of warfarin as a stroke prevention therapy in patients with nonvalvular atrial fibrillation is associated with a lower rate of residual stroke or systemic embolism compared with previous data, according to a recent study published in the Archives of Internal Medicine.
Youth diagnosed with type 2 diabetes may require a combination treatment or insulin therapy within a few years after diagnosis, according to a study published online April 29 in the New England Journal of Medicine.
Children with juvenile idiopathic arthritis were at twice the risk of infection compared with children with attention-deficit hyperactivity disorder, according to a study published May 1 in Arthritis & Rheumatism.
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians. Register now (it's free and quick) or Find out more.
Keep visiting FormularyJournal.com for fresh content, news, opinions, editor's blogs and more.
With specialty drug products representing the fastest growing component of today's drug expenditures, which of the following would you rate as the most important service a specialty pharmacy can provide in helping to optimize the quality and cost-efficiency of specialty pharmaceutical care?
Waste management
7%
Patient risk assessment and education
10%
Managing prior authorization of specialty products
Resources: 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
